Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]        
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (5,031,843) $ (5,196,438) $ (12,202,149) $ (9,611,146)
Foreign currency translation adjustment (47,501)   (51,646)  
Comprehensive loss to MAIA Biotechnology, Inc. shareholders $ (5,079,344) $ (5,196,438) $ (12,253,795) $ (9,611,146)